The market taxonomy for Complement-dependent Cytotoxicity Testing Services further divides by service type, each reflecting distinct methodological approaches and cost structures. The dominant in‑vitro CDC assay segment, representing roughly 55 % of service revenue, includes sub‑modalities such as flow‑cytometry‑based CDC, which quantifies target‑cell lysis via fluorescence, and ELISA‑based CDC, which measures complement deposition markers. Ex‑vivo whole‑blood assays account for about 25 % and capture complement activity in a physiologically relevant matrix, with subtypes like heparin‑anticoagulated and citrate‑anticoagulated protocols that affect assay sensitivity. The emerging cell‑based reporter assay niche contributes near 15 % and leverages engineered reporter cells that emit luminescent signals upon complement activation, offering higher throughput and reduced variability. Finally, high‑throughput screening (HTS) platforms occupy the remaining 5 %, employing automated liquid‑handling and multiplexed readouts to evaluate large antibody libraries. Each type’s share directly maps to its technical complexity, regulatory acceptance, and client demand, collectively shaping the overall market size and informing provider specialization strategies. This detailed segmentation aligns with the broader Complement-dependent Cytotoxicity Testing Services segmentation framework.
